Gan & Lee Pharmaceuticals

Science & Excellence

Founded 1998 China

China 379 employees Private Equity Total: $46.46M Biopharma, Biotechnology +2

Gan & Lee Pharmaceuticals is a leading player in the biopharma, biotechnology, health care, and pharmaceutical industries, with a focus on diabetes diagnosis and treatment since its establishment in 1998. The company's success story began with the development of China's first domestic insulin analog, propelling it to a prominent position as a major supplier of insulin in China. With a commitment to broaden its global coverage, Gan & Lee has established a strong presence in the industry, including a US subsidiary in New Jersey and its second domestic drug production site in Linyi City, Shandong, China. The company's vision goes beyond diabetes, as evidenced by its extensive clinical development program exploring new chemical entities and biologics for various therapeutic areas, including cardiovascular disease, metabolic disease, and cancer. Gan & Lee's dedication to providing patient-focused solutions and impacting lives positively reflects in its Slogan: "Science & Excellence". The company's state-of-the-art buildings and Good Manufacturing Practice (GMP) facilities in Beijing, China demonstrate its commitment to quality and innovation. Additionally, its Private Equity Round investment at 01 January 2015, led by Hillhouse Investment, further solidifies its position in the market and amplifies its potential for global expansion. As Gan & Lee steers towards venturing into North America, Europe, and other regions, it encapsulates a promising prospect for investors seeking vibrant opportunities in the pharmaceutical sector.

Funding Stage	Amount	Investors	Lead Investors	Date
Private Equity Round	Undisclosed	1	Hillhouse Investment	01 Jan 2015
Series B	Undisclosed	1	Qiming Venture Partners	01 Feb 2012
Series B	$30.23M	3	Goldman Sachs, Qiming Venture Partners +1	01 May 2011
Series A	$16.24M	1	Qiming Venture Partners	01 Dec 2009

Funding Stage

Amount

Investors

Lead Investors

Date

Private Equity Round

Undisclosed

Hillhouse Investment

01 Jan 2015

Series B

Undisclosed

Qiming Venture Partners

01 Feb 2012

Series B

$30.23M

Goldman Sachs, Qiming Venture Partners +1

01 May 2011

Series A

$16.24M

Qiming Venture Partners

01 Dec 2009

FAQ About Gan & Lee Pharmaceuticals

Science & Excellence

Gan & Lee Pharmaceuticals was founded in 1998.

Gan & Lee Pharmaceuticals is headquartered in China.

Gan & Lee Pharmaceuticals operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on Biopharmaceuticals, Insulin Analogues, Diabetes Treatment and Clinical Development.

Gan & Lee Pharmaceuticals has approximately 379 employees.

Gan & Lee Pharmaceuticals has completed 4 funding rounds, raising a total of $46.46M. The latest funding stage is Private Equity.

Top alternatives and competitors to Gan & Lee Pharmaceuticals include Innovent Biologics, Mercodia, Biocon, GenFleet Therapeutics, Genmab. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Gan & Lee Pharmaceuticals and Innovent Biologics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Gan & Lee Pharmaceuticals

General Information

Discover More

About Gan & Lee Pharmaceuticals

Funding Rounds & Investors (4)

Gan & Lee Pharmaceuticals Alternatives & Competitors

FAQ About Gan & Lee Pharmaceuticals